The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

MSD CEF outperforms peers and ETFs, offering a 12% yield with no leverage and a diversified, ... I have no business relationship with any company whose stock is mentioned in this article.

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports.

MSD in the Philippines has earned Bronze in the “Community Impact and Engagement” category at the inaugural Corporate Social ...

MSD in the Philippines has earned Bronze in the “Community Impact and Engagement” category at the inaugural Corporate Social ...

MSD’s randomised, multicenter, open-label, dose confirmation and expansion waveLINE-003 study is investigating the zilovertamab vedotin triplet combination therapy as a treatment for relapsed or ...

A mentoring program is provided at three levels to coach each participant in career and leadership development ...

Discover why MSD may face challenges as a hedge against a weaker dollar. Explore its premium valuation, low spreads, and potential downside.

The Philippine College of Occupational Medicine (PCOM) and healthcare company MSD in the Philippines have joined forces to integrate cancer prevention into workplace health programs, reinforcing early ...

COPENHAGEN - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has entered into an option and license agreement with pharmaceutical giant MSD, known as Merck & Co., Inc. in the U.S ...

NEARLY 70 employees at pharmaceutical company MSD Carlow have donated over 600 hours of their time to local charities and ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma (DLBCL), has demonstrated promise in a Phase II/III study, as the company ...